# ImmuCell Corporation Reports 46% Jump in Q3 Sales to $8.0 Million

- URL: https://stocks.freetheai.org/news/immucell-corporation-reports-46-jump-in-q3-sales-to-8-0-million-c1f9f4
- Published: 2026-10-12T20:05:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ICCC](https://stocks.freetheai.org/symbols/NASDAQ-ICCC)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ImmuCell Corporation (ICCC) generated preliminary Q3 2026 sales of $8.0 million, representing a 46% increase compared to the same period last year. For the first nine months of 2026, cumulative sales grew 27.8% year over year to reach $25.6 million. Domestic sales in the U.S. expanded 29.2% to $6.9 million during the quarter.

The revenue expansion was supported by growth across key product offerings. Third-quarter sales of Tri-Shield increased 51% compared to the prior year, while Dual-Force sales rose 36% and feed product sales grew 37%. The broad revenue gains reflect strong demand across the company's product portfolio.

Management plans to discontinue early sales pre-announcements moving forward. Investors will gain further insight into overall profitability, gross margins, and net earnings when full Q3 financial results are reported on November 13, 2026.

## Key points

- ImmuCell reported preliminary Q3 2026 sales of $8.0 million, up 46% year over year.
- Nine-month cumulative revenue rose 27.8% to $25.6 million.
- Domestic U.S. sales grew 29.2% to $6.9 million during the third quarter.
- Product growth was led by Tri-Shield, which surged 51% compared to the previous year.
- Management will end early sales updates and report full financial results on November 13, 2026.

## Questions and answers

### What were ImmuCell's Q3 2026 sales?

ImmuCell Corporation reported preliminary Q3 2026 sales of $8.0 million, up 46% year over year.

### When will ImmuCell discuss its full Q3 financial results?

Management will review complete third-quarter financial results, including margins and earnings, on November 13, 2026.